Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer

Cell Rep. 2022 Dec 27;41(13):111890. doi: 10.1016/j.celrep.2022.111890.

Abstract

Ovarian cancer (OC) remains a clinical challenge for its difficulty in early diagnosis and insensitivity to treatments. Gut microbiota modulate multiple carcinoma progression through immunoregulation. The relationship between OC and gut microbiota has not been fully characterized. We find that the feces of patients with OC demonstrate different characteristics from benign controls. After fecal microbiota transplantation (FMT) from patients with OC into OC-bearing mice, the tumor development accelerates. Further, an Akkermansia supplementation with FMT significantly suppresses OC progression in mice. RNA sequencing of tumors shows that T cell activation pathways are upregulated after Akkermansia supplementation with FMT. Moreover, acetate accumulation accompanies Akkermansia abundance elevation, which is associated with enhanced interferon γ (IFNγ) secretion of CD8+ T cells and also its tumor-killing property. This work highlights the importance of protective gut microbiome in immune surveillance of OC, which connects accumulation of acetate and the cytotoxic function of CD8+ T cells by increasing IFNγ secretion.

Keywords: Akkermansia; CP: Cancer; CP: Microbiology; T cells; fecal microbiota transplantation; gut homeostasis; immune microenvironment; ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Akkermansia
  • Animals
  • CD8-Positive T-Lymphocytes
  • Dietary Supplements
  • Fecal Microbiota Transplantation*
  • Feces
  • Female
  • Humans
  • Mice
  • Ovarian Neoplasms* / therapy